Cargando…
Targeting c-Jun inhibits fatty acid oxidation to overcome tamoxifen resistance in estrogen receptor-positive breast cancer
Tamoxifen-based endocrine therapy remains a major adjuvant therapy for estrogen receptor (ER)-positive breast cancer (BC). However, many patients develop tamoxifen resistance, which results in recurrence and poor prognosis. Herein, we show that fatty acid oxidation (FAO) was activated in tamoxifen-r...
Autores principales: | Jiang, Cen, Zhu, Youzhi, Chen, Huaying, Lin, Junyu, Xie, Ruiwang, Li, Weiwei, Xue, Jiajie, Chen, Ling, Chen, Xiangjin, Xu, Sunwang |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10558541/ https://www.ncbi.nlm.nih.gov/pubmed/37803002 http://dx.doi.org/10.1038/s41419-023-06181-5 |
Ejemplares similares
-
(68)Ga-Labeled Fibroblast Activation Protein Inhibitor PET/CT for the Early and Late Prediction of Pathologic Response to Neoadjuvant Chemotherapy in Breast Cancer Patients: A Prospective Study
por: Chen, Ling, et al.
Publicado: (2023) -
Loss of ID3 drives papillary thyroid cancer metastasis by targeting E47-mediated epithelial to mesenchymal transition
por: Xu, Sunwang, et al.
Publicado: (2021) -
SENP3 promotes tumor progression and is a novel prognostic biomarker in triple-negative breast cancer
por: Zhu, Youzhi, et al.
Publicado: (2023) -
Aspirin regulation of c-myc and cyclinD1 proteins to overcome tamoxifen resistance in estrogen receptor-positive breast cancer cells
por: Cheng, Ran, et al.
Publicado: (2017) -
Epigenetic activation of the elongator complex sensitizes gallbladder cancer to gemcitabine therapy
por: Xu, Sunwang, et al.
Publicado: (2021)